Korea Institute of Science and Technology (KIST) enters technology transfer agreement with Huons BioPharma
The collaboration between KIST and Huons BioPharma will span 14 months.
(Image credit: AdobeStock/PhotoStar)
The Korea Institute of Science and Technology (KIST) has entered into a technology transfer agreement with Huons BioPharma for the development and commercialization of a peptide treatment for dry macular degeneration.
The collaboration between KIST and Huons BioPharma will span 14 months, during which the 2 institutions will operate a joint research lab and conduct global clinical trials. This initiative aligns with the goals of the KIST Natural Product New Drug Business Group, which has been actively working on identifying new drug materials from natural sources to treat age-related intractable diseases such as macular degeneration and cancer.1
Oh Sang-rok, president of KIST, shared thoughts of this collaboration, saying, "The cooperation between KIST and Huons BioPharma will be a representative example of the BP Plus project, which actively supports the commercialization process of companies that have signed technology transfer contracts." He added, "It is even more meaningful as it is the first achievement of the mission-oriented research institute implemented by KIST this year."1
Kim Young-mok, CEO of Huons BioPharma, was also quoted on the partnership, saying, "We will secure a promising pipeline related to the research and development of peptide treatments in the era of aging, thereby enhancing our competitiveness in the elderly disease market."1
The BP Plus project, an initiative by KIST, aims to bridge the gap between research and market-ready products by providing resources and support to companies that license KIST's technologies.1
